NanoViricides Inc., a publicly traded clinical stage company specializing in broad-spectrum antivirals, announced that it has filed an application with the US FDA Office of Orphan Products Development (OOPD) for Orphan Drug Designation $(ODD)$ for its drug candidate NV-387 as a treatment for measles. If approved, the designation would provide NanoViricides with incentives such as tax credits for clinical trials, exemption from certain user fees, and up to seven years of market exclusivity upon drug approval. NV-387 is described as a broad-spectrum antiviral that has shown in vivo activity against the measles virus in animal models. There is currently no approved drug for the treatment of measles.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1135491) on February 10, 2026, and is solely responsible for the information contained therein.